Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04914897 · ClinicalTrials.gov registry record · Phase 2
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT04914897 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 106 participants.
The verdict
NCT04914897, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: * To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. * To assess other indicators of antitumor activity. * To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab. * To assess the immunogenicity of SAR444245.
Interventions
- DRUG Pembrolizumab
- DRUG THOR-707
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04914897
The ClinicalTrials.gov registry entry for NCT04914897 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04914897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04914897 about?
NCT04914897 is a clinical study titled "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)". The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: * To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. * To assess other indicato...
What is the current status of trial NCT04914897?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2021-09-23. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT04914897?
The interventions under investigation include: Pembrolizumab (DRUG), THOR-707 (DRUG).
Who is sponsoring clinical trial NCT04914897?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.